Navigation Links
'Renal Assist Device' reduces risk of death from acute kidney failure
Date:3/4/2008

For patients with acute kidney injury (AKI), an external device containing human kidney cells promotes recovery of the injured kidneys and significantly reduces the risk of death, according to a preliminary clinical study published in the May Journal of the American Society of Nephrology.

The experimental renal tubule assist device (RAD) appears safe and effective for desperately ill patients with AKI. "Deployment of the RAD was associated with remarkably better outcomes for these patientsspeeding recovery of kidney function and reducing risk of death by half," comments Dr. H. David Humes of University of Michigan, one of the study authors.

Patients with AKI have sudden loss of kidney function, resulting from a wide range of possible causes (such as blood loss or toxic injury). The goal of treatment is to replace lost kidney function through dialysis and related techniques until the kidneys have time to recover. However, even with treatment, the risk of death during an episode of AKI is 50 percent or higher.

In the new study, 40 of 58 patients with AKI were randomly assigned to treatment with the RAD, in addition to standard renal replacement therapy. The RAD is a conventional blood filter device lined with human renal tubule cells, grown from donor kidneys. "The cells are made available to carry out subtle metabolic and endocrine functions that the patient's failing kidneys can no longer perform, thereby staunching a cascading decline in the patient's health and allowing time for the patient's own organs to recover," Dr. Humes explains.

Outcomes were significantly better for AKI patients treated with the RAD. After one month, 33 percent of patients in the RAD group had died, compared to 61 percent of those treated with renal replacement therapy only. Patients who received the RAD were also more likely to be alive after six months. With adjustment for other factors, the risk of death was about 50 percent lower in the RAD group.

Patients in the RAD group also had a shorter time to return of kidney function. Overall, kidney function recovered in 53 percent of patients with RAD, compared to 28 percent without RAD. In both groups, about 20 percent of patients survived but never recovered kidney function, requiring chronic dialysis.

Although the initial results are encouraging, the benefits of RAD treatment need to be confirmed in larger studies. In addition, the researchers need to study the effects of changes in the design of the RAD, which are needed to accommodate mass production.

In addition to improving the outcomes of AKI, the results may point the way toward entirely new classes of cell-based and tissue-engineered therapies. "The ability to harness vital processes of cells, to target their living molecular machinery on restoring critical substances which have become disordered by disease, has vast implications for the future of medicine," says Dr. Humes. "Particularly, we are encouraged that we can develop a related device to treat chronic renal failurea wearable kidney that performs natural functions unachievable through man-made technology alone."


'/>"/>

Contact: Shari Leventhal
sleventhal@asn-online.org
202-416-0658
American Society of Nephrology
Source:Eurekalert

Related medicine news :

1. Statement by Robert D. Foreman, President of The Kidney Care Council, Regarding the HHS Report to Congress A Design for a Bundled End Stage Renal Disease Prospective Payment System
2. PLC Systems Files IDE Supplement to Begin Pivotal Study of RenalGuard(TM) and Provides Update on Planned Development Timeline
3. PLC Systems Receives CE Mark Approval for RenalGuard(TM)
4. UT Southwestern: Patients with mild Cushing syndrome may benefit from adrenalectomy
5. Follow-up imaging of benign-appearing incidental adrenal masses is unnecessary
6. Renal Solutions, Inc. Announces Acquisition by Fresenius Medical Care
7. Serum carcinoembryonic antigen level can reflect adrenal adenoma
8. FDA Approves MIRCERA(R): First Renal Anemia Treatment with Monthly Maintenance Dosing
9. PLC Medical Systems to Display RenalGuard(TM) During Renal Week 2007
10. Nephrologists summarize new renal research during public policy news briefing at Renal Week
11. Renal Solutions, Inc. Announces FDA 510(k) Clearance of New Design of the Allient(R) Sorbent Hemodialysis System for Chronic and Acute Hemodialysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... TherapySites, the leading website and ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to extend ... exclusive benefits and promotional offers. , "TCA is extremely excited about this new ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... edge technology to revolutionize the emergency ambulance transport experience for the millions of ... of how Uber has disrupted the taxi industry through the use of technology. ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect Plugin ... whole new perspective by using the title layers in ProSlice Levels to split-up ... Levels contains over 30 Different presets to choose from. FCPX users can ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
Breaking Medicine Technology: